Xiangyong Hao

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Venues

Human resources for health

BMC public health

Journal of translational medicine

Gut and liver

Gansu Provincial Hospital

Sichuan University West China Hospital (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Gansu Provincial Hospital Sep 01 2009

China

Deputy Chief Physician :: Department of General Surgery

Education History

Sichuan University West China Hospital Sep 01 2016 - Jun 01 2019

China

PHD :: School of Clinical Medicine

Lanzhou University Sep 01 2007 - Jun 01 2009

China

MSC :: School of Clinical Medicine

Publications

Yanfei Shen, Gaiyun Li, Zhiguo Tang, Qi Wang, Zurong Zhang, Xiangyong Hao, Xuemei Han
Analysis of the characteristics, efficiency, and influencing factors of third-party mediation mechanisms for resolving medical disputes in public hospitals in China. BMC public health 24 (1) (2024)
Yanfei Shen, Gaiyun Li, Zhiguo Tang, Qi Wang, Zurong Zhang, Xiangyong Hao, Xuemei Han
Analysis of the characteristics, efficiency, and influencing factors of third-party mediation mechanisms for resolving medical disputes in public hospitals in China. BMC public health 24 (1) (2024)
Yanfei Shen, Gaiyun Li, Zhiguo Tang, Qi Wang, Zurong Zhang, Xiangyong Hao, Xuemei Han
Analysis of the characteristics, efficiency, and influencing factors of third-party mediation mechanisms for resolving medical disputes in public hospitals in China. BMC public health 24 (1) (2024)
Xin Su, Jian Li, Xiao Xu, Youbao Ye, Cailiu Wang, Guanglong Pang, Wenxiu Liu, Ang Liu, Changchun Zhao, Xiangyong Hao
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy. Journal of translational medicine 22 (1) (2024)
Xin Su, Jian Li, Xiao Xu, Youbao Ye, Cailiu Wang, Guanglong Pang, Wenxiu Liu, Ang Liu, Changchun Zhao, Xiangyong Hao
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy. Journal of translational medicine 22 (1) (2024)
Yanfei Shen, Sheng Lei, Qi Wang, Hongjing Wang, Xiangyong Hao, Hui Cai
Analysis of the characteristics and risk factors affecting the judgment results of medical damage liability disputes in 3172 second-instance and retrial cases in China. Human resources for health 21 (1) (2023)
Yanfei Shen, Sheng Lei, Qi Wang, Hongjing Wang, Xiangyong Hao, Hui Cai
Analysis of the characteristics and risk factors affecting the judgment results of medical damage liability disputes in 3172 second-instance and retrial cases in China. Human resources for health 21 (1) (2023)
Yanfei Shen, Sheng Lei, Qi Wang, Hongjing Wang, Xiangyong Hao, Hui Cai
Analysis of the characteristics and risk factors affecting the judgment results of medical damage liability disputes in 3172 second-instance and retrial cases in China. Human resources for health 21 (1) (2023)
Shaoming Song, Mingzhen Bai, Xiaofei Li, Shiyi Gong, Wenwen Yang, Caining Lei, Hongwei Tian, Moubo Si, Xiangyong Hao, Tiankang Guo
Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma. Expert review of molecular diagnostics 22 (3) (2022)
Liangliang Xu, Lian Li, Peng Wang, Ming Zhang, Yanfang Zhang, Xiangyong Hao, Lvnan Yan, Bo Li, Tianfu Wen, MingQing Xu
Novel Prognostic Nomograms for Hepatocellular Carcinoma Patients with Microvascular Invasion: Experience from a Single Center. Gut and liver 13 (6) (2020)

Xiangyong Hao.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Xiangyong Hao